Detecting KRAS2 Mutations to Differentiate Pancreatic Cancer from Chronic Pancreatitis
Author Information
Author(s): Maire F, Micard S, Hammel P, Voitot H, Lévy P, Cugnenc P-H, Ruszniewski P, Puig P Laurent
Primary Institution: Fédération Médico-Chirurgicale d'Hépato-Gastroentérologie, Hôpital Beaujon, AP-HP, France
Hypothesis
The study aims to evaluate the value of KRAS2 mutations detection in circulating DNA to differentiate pancreatic cancer from chronic pancreatitis.
Conclusion
Detection of KRAS2 mutations in circulating DNA has low sensitivity but high specificity for diagnosing pancreatic cancer, especially when serum carbohydrate antigen 19.9 levels are normal or inconclusive.
Supporting Evidence
- KRAS2 mutations were found in 22 patients (47%) with pancreatic cancer and in four controls (13%).
- The combination of KRAS2 and carbohydrate antigen 19.9 testing increased diagnostic sensitivity to 98%.
- None of the controls with chronic pancreatitis developed pancreatic cancer within the 36 months of follow-up.
Takeaway
Researchers looked for specific mutations in the blood of patients to see if they could tell the difference between pancreatic cancer and chronic pancreatitis. They found that while the test isn't perfect, it can be very helpful.
Methodology
The study involved isolating circulating DNA from serum samples of patients with pancreatic adenocarcinoma and controls with chronic pancreatitis, followed by testing for KRAS2 mutations using PCR.
Limitations
The study's follow-up period was too short to demonstrate an increased risk of cancer in patients with chronic pancreatitis and serum KRAS2 mutations.
Participant Demographics
47 patients with pancreatic adenocarcinoma (26 males, median age 65 years) and 31 controls with chronic pancreatitis (26 males, median age 48 years).
Statistical Information
P-Value
p<0.002
Statistical Significance
p<0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website